Overview

Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2018-11-28

Target enrollment:

Participant gender:

Summary

The purpose is to assess the Safety, Tolerability, and Pharmacodynamics effect of IONIS DGAT2Rx in up to 45 Adult Patients with Type 2 Diabetes.

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.